The Russia-Japan Investment Fund invests alongside partners in R-Pharm, a leading Russian pharmaceutical company

Press release, 14.12.2018

Moscow, December 14, 2018 – The Russia-Japan Investment Fund (RJIF, launched by the Russian Direct Investment Fund (RDIF) and Japan Bank for International Cooperation, and advised by RDIF and JBIC IG Partners) and RDIF, alongside international sovereign wealth funds, announce an investment in R-Pharm, a leading Russian pharmaceutical company.

R-Pharm partners with various international pharmaceutical companies including Japanese ones. Mitsui & Co., Ltd., a leading Japanese trading and investment company, acquired 10% of R-Pharm’s shares last year.

***

Russia-Japan Investment Fund was established to pursue and implement attractive investment projects to promote economic, trade and investment cooperation between Japan and Russia. Priority sectors identified for cooperation include healthcare, development of smart cities and sustainable technologies, energy, cutting-edge technologies and developing industries and export in the Russian Far Eastern District, as well as other initiatives that will strengthen the trade and economic relations between the two countries. Further information can be found at www.rjif.org

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 70 projects with foreign partners totaling more than 1.4 trillion rubles and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 700,000 people, and generate revenues which equate to more than 5% of Russia’s GDP. RDIF established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than 40 billion dollars. Further information can be found at www.rdif.ru

R-Pharm was founded in 2001 by Alexey Repik. It is one of the most innovative pharmaceutical companies in Russia that employs over 3,600 highly qualified specialists. The company is involved in R&D, manufacturing, promotion and distribution of medicines used in hospital and specialty care. Further information can be found at www.r-pharm.com

For additional information contact:
Arseniy Palagin
Russian Direct Investment Fund
Press Secretary
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru

Andrew Hayes / Andrew Leach
Hudson Sandler
Tel: +44 (0) 20 7796 4133

Anastasiya Khrustaleva
R-Pharm Group
Head of Media Relations
Mobile: +7 926 370 67 55
E-mail: khrustaleva@rpharm.ru

Back